AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01261416 — intervention group
Intervention type: DRUG
Intervention: levetiracetam
Description: Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
Study NCT02923115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
Study NCT02923115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
Study NCT02923115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Subcutaneous injection 1 mg/kg twice daily
Study NCT02923115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous injection 1 mg/kg twice daily
Study NCT06416761 — intervention group
Intervention type: GENETIC
Intervention: genetic polymorphisms
Study NCT01938742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Description: Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, \& 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
Study NCT01938742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
Study NCT03801759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose 600 mg
Study NCT03801759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral Furosemide
Study NCT03801759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Oral Adefovir
Study NCT03801759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral Digoxin
Study NCT02424656 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: EEG-functional MRI, structural MRI, diffusion MRI
Study NCT02424656 — intervention group
Intervention type: PROCEDURE
Intervention: TMS-EEG
Description: Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
Study NCT02424656 — intervention group
Intervention type: PROCEDURE
Intervention: FDG-PET
Study NCT02424656 — intervention group
Intervention type: OTHER
Intervention: Clinical scales
Description: Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
Study NCT02602561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB
Study NCT02602561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01804530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX7486 TsOH
Description: PLX7486 TsOH capsules, 50mg
Study NCT03638752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive education group
Description: The details of Comprehensive education are as follows:~1. introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~2. instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~3. provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~4. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~5. inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~6. inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting.
Study NCT03999229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNO
Description: S-nitrosylating agent (SNO) Inhalation
Study NCT03999229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SNO
Description: S-nitrosylating agent (SNO) Inhalation
Study NCT03999229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline transfusion
Study NCT03999229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell
Description: Blood transfusion (RBCs)
Study NCT04254731 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)
Study NCT02121405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectectomy
Description: Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
Study NCT02121405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectectomy
Description: Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
Study NCT02121405 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
Study NCT02121405 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
Study NCT02121405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
Study NCT02121405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
Study NCT02121405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
Study NCT02121405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
Study NCT01205776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Those patients receiving CABG
Study NCT02863094 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation
Study NCT02863094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Study NCT02263430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Study NCT02263430 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Study NCT03458442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based surgical training
Description: Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course.
Study NCT03458442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical training
Description: Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
Study NCT03458442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard surgical training
Description: Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
Study NCT03426592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3, 10000 Intl Units Oral Capsule
Description: Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study.
Study NCT03426592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study.
Study NCT01376999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-r (Follicule stimulate hormone)
Description: Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
Study NCT01376999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH-r (Follicule stimulate hormone)
Description: Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
Study NCT03139851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide 50mg
Description: One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT03139851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab 100 MG in 4 ML Injection
Description: IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT03428152 — intervention group
Intervention type: PROCEDURE
Intervention: superior hypogastric block
Description: superior hypogastric blockade during surgery
Study NCT00108355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
Study NCT00108355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Saline Infusion (Albumin placebo)
Description: Intravenous saline Infusion (Albumin placebo)
Study NCT00523848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: IV
Study NCT00523848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: IV
Study NCT00523848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Oral
Study NCT03832764 — intervention group
Intervention type: DEVICE
Intervention: ANSPEC-PRO
Description: Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
Study NCT05261542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry
Description: evaluation of intraoperative flow cytometry in detecting cancer cells in colorectal epithelium
Study NCT01155856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital
Description: For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
Study NCT04752956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total nasal symptom score (TNSS)
Description: TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.
Study NCT00108355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine oral tablet at 10 mg three times a day.
Study NCT00108355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tablet (Midodrine placebo)
Description: Oral tablet (Midodrine placebo) three times a day
Study NCT04752956 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)
Description: PRQLQ, is a self-administered, disease-specific questionnaire, evaluating physical, emotional, and social status of individuals with AR. It contains 23 items in 5 domains: nose symptoms (RS), eye symptoms (ES), practical problems (PF), activity limitation (RL) and other symptoms (OS). One score is given to each domain. 7-point scale (from 0, not problematic; to 6, very problematic). The overall score is derived from the average score of all items (20). In our study, the Turkish validated form of PRQLQ was used~Patients will be asked to answer PRQLQ questions at the end of each week during treatment. At the end of the treatment, an average of 4 weeks will be taken as the PRQLQ score. Basal PRQLQ questions will be evaluated by the participants based on 4 weeks prior to treatment.
Study NCT04752956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal cytology
Description: In anterior rhinoscopy, nasal cytology will be scraped off the middle part of the lower turbinate with the help of a small sterile cotton swab. The cellular material obtained will be fixed by air drying on a glass slide and then stained by the May-Grünwald-Giemsa method. Preparations that do not contain respiratory epithelium or contain less than 10 epithelium at high magnification will be excluded from the study. A percentage of cells per 100 cells will be reported. NECs (nasal eosinophilic count) will be evaluated according to the quantitative classification of Gelardi et al. An experienced cytologist who is blind to the study groups will perform this test. Eosinophil percentages in nasal smears of all patients will be evaluated before and after the treatment.
Study NCT04752956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: anterior rhinomanometry
Description: Children's right, left and total nasal airway resistance (NAR) and nasal airflow (NAF) will be measured with active anterior rhinomanometry ZAN 100 USB Rhinomanometry (Longmont, Colo., USA). In the evaluation, the NAR- pressure difference / air flow (R = P / V) formula will be used at a constant 150 Pascal prescribed by the European Rinomanometry Standardization Committee in 1984. After the patient is rested for 20 minutes, measurements will be made at 20-22 ° C and the nasal secretion will be cleared. NAR and NAF values of the participants will be measured before starting treatment and 4 weeks after treatment.
Study NCT00580151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 3-5 microgram per kilogram every 6 hours for 10 days
Study NCT00580151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 dose every 6 hours
Study NCT03514459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach
Description: SAIA has five steps. The first step uses an Excel-based tool to quantify drop- offs, or people who did not progress, in each step of a process (Figure 1). This tool also allows the user to see the downstream effect when improving one step in the cascade, and holding the other steps constant. Step 2 involves process flow mapping with clinic staff to identify modifiable bottlenecks in the process. Step 3 develops and implements a workflow modification to address a bottleneck identified in step 2 (continuous quality improvement \[CQI\] step). Step 4 assesses impact of the modification and recalculates the cascade analysis in step 1 (CQI step). Step 5 repeats the cycle for CQI. SAIA draws from systems engineering in the Toyota Production Systems and from research in LMICs. Studies in quality improvement in LMICs highlight that CQI processes led to more sustainable, effective, and appropriate interventions (42-44).
Study NCT01757093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Tube Compensation plus CPAP
Description: SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
Study NCT01757093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Tube Compensation plus CPAP
Description: SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
Study NCT01757093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: SPONTANEOUS BREATHING TRIAL WITH CPAP
Study NCT01757093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: SPONTANEOUS BREATHING TRIAL WITH CPAP
Study NCT04425057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training
Study NCT00929370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine Transporter-1 inhibitor
Description: GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).